Growth hormone-releaser diet attenuates β-amyloid(1-42)-induced cognitive impairment via stimulation of the insulin-like growth factor (IGF)-1 receptor in mice

Journal of Pharmacological Sciences

Volumn 109, Issue 1, 2009, Pages 139-143

  Shin, Eun Joo ^a   Chae, Jong Seok ^a   Park, Seok Joo ^a   Kim, Sun Cheol ^a   Koo, Kyo Hwan ^a   Yamada, Kiyofumi ^b   Nabeshima, Toshitaka ^c   Kim, Hyoung Chun ^a  

^a Kangwon National University   (South Korea)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MEIJO UNIVERSITY   (Japan)

Author keywords

Growth hormone releaser; Insulin like growth factor (IGF) 1 receptor; amyloid

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; GROWTH HORMONE; JB 1; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIETARY INTAKE; FEAR; GROWTH HORMONE RELEASE; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; RECEPTOR UPREGULATION;

EID: 58649109826     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08145SC     Document Type: Article

References (15)

1. Khorram O. Use of growth hormone and growth hormone secretagogues in aging: help or harm. Clin Obstet Gynecol. 2001;44:893-901.
2. Chromiak JA, Antonio J. Use of amino acids as growth hormone-releasing agents by athletes. Nutrition. 2002;18:657-661.
3. Shin EJ, Jhoo JH, Nabeshima T, Jhoo WK, Kwon MS, Lim YK, et al. Growth hormone releaser attenuates β-amyloid (1-42)-induced memory impairment in mice. J Pharmacol Sci. 2005;99: 117-120.
4. Quesada A, Etgen AM. Functional interactions between estrogen and insulin-like growth factor-1 in the regulation of alpha 1β-adrenoceptors and female reproductive function. J Neurosci. 2002;22:2401-2408.
5. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 2003;17:50-52.
6. Chao LP, Wolfgram F. Spectrophotometric assay for choline acetyltransferase. Anal Biochem. 1972;46:114-118.
7. Kopchick JJ, Andry, JM. Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab. 2000;71:293-314.
8. Pan W, Yu Y, Cain C, Nyberg F, Courand PO, Kastin A. Permeation of growth hormone across the blood-brain barrier. Endocrinology. 2005;146:4898-4904.
9. Obermayr RP, Mayerhofer L, Knechtelsdoefer M, Mersich N, Huber ER, Geyer G, et al. The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. Exp Gerontol. 2005;40:157-163.
10. Mayeux R, Sano M. Treatment of Alzheimer's disease. New Eng J Med. 1999;341:1670-1679.
11. Sonntag W, Lynch C, Thornton P, Khan A, Bennett S, Ingram R. The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain ageing. J Anat. 2000;197:575-585.
12. Lo DC. Neurotrophic factors and synaptic plasticity. Neuron. 1995;15:979-981.
13. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356.
14. Kim HC, Yamada K, Nitta A, Olariu A, Tran MH, Mizuno M, et al. Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivo. Neuroscience. 2003;119:399-419.
15. Tran MH, Yamada K, Olariu A, Mizuno M, Ren XH, Nabeshima T. Amyloid β-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J. 2001;15:1047-1049.